[go: up one dir, main page]

NO975742D0 - Reversible cysteinproteasehemmere - Google Patents

Reversible cysteinproteasehemmere

Info

Publication number
NO975742D0
NO975742D0 NO975742A NO975742A NO975742D0 NO 975742 D0 NO975742 D0 NO 975742D0 NO 975742 A NO975742 A NO 975742A NO 975742 A NO975742 A NO 975742A NO 975742 D0 NO975742 D0 NO 975742D0
Authority
NO
Norway
Prior art keywords
protease inhibitors
cysteine protease
reversible cysteine
reversible
inhibitors
Prior art date
Application number
NO975742A
Other languages
English (en)
Other versions
NO975742L (no
Inventor
Jeffrey Lee Klaus
David Rasnick
James T Palmer
Elaine Yee-Lin Kuo
Original Assignee
Arris Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharm Corp filed Critical Arris Pharm Corp
Publication of NO975742D0 publication Critical patent/NO975742D0/no
Publication of NO975742L publication Critical patent/NO975742L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/18—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
NO975742A 1995-06-07 1997-12-05 Reversible cystein proteasehemmere NO975742L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47499395A 1995-06-07 1995-06-07
PCT/US1996/008559 WO1996040737A1 (en) 1995-06-07 1996-06-03 Reversible cysteine protease inhibitors

Publications (2)

Publication Number Publication Date
NO975742D0 true NO975742D0 (no) 1997-12-05
NO975742L NO975742L (no) 1998-02-05

Family

ID=23885799

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975742A NO975742L (no) 1995-06-07 1997-12-05 Reversible cystein proteasehemmere

Country Status (15)

Country Link
US (1) US6030946A (no)
EP (1) EP0832099A1 (no)
JP (1) JPH11507045A (no)
KR (1) KR19990022395A (no)
CN (1) CN1192219A (no)
AR (1) AR002328A1 (no)
AU (1) AU723658B2 (no)
CA (1) CA2222972A1 (no)
CZ (1) CZ390697A3 (no)
NO (1) NO975742L (no)
NZ (1) NZ309560A (no)
PL (1) PL323710A1 (no)
TW (1) TW438591B (no)
WO (1) WO1996040737A1 (no)
ZA (1) ZA964751B (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR19990067184A (ko) * 1995-10-30 1999-08-16 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
SK88997A3 (en) 1995-10-30 1998-05-06 Smithkline Beecham Corp Method of inhibiting cathepsin k
EP0934293A1 (en) * 1996-07-30 1999-08-11 Arris Pharmaceutical Corporation Novel compounds and compositions for treating diseases associated with tryptase activity
US5830850A (en) * 1996-08-28 1998-11-03 Mount Sinai School Of Medicine Of The City Of New York Methods for the treatment of bone resorption disorders, including osteoporosis
FR2760193B1 (fr) * 1997-02-28 1999-05-28 Transgene Sa Lipides et complexes de lipides cationiques et de substances actives, notamment pour la transfection de cellules
US6359134B1 (en) 1997-05-30 2002-03-19 Takeda Chemical Industries, Ltd. Sulfonamide derivatives, their production and use
AU2298899A (en) 1998-02-05 1999-08-23 Takeda Chemical Industries Ltd. Sulfonamide derivatives, process for producing the same and utilization thereof
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
US6294539B1 (en) * 1999-01-19 2001-09-25 Advanced Syntech, Llc Heterocyclic hydroxamic acid derivatives as MMP inhibitors
WO2000051998A1 (en) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Compounds useful as reversible inhibitors of cathepsin s
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
HRP20020221A2 (en) * 1999-09-13 2005-10-31 Boehringer Ingelheim Pharmaceuticals Inc. Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
US6583137B1 (en) 1999-11-10 2003-06-24 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
AU1588901A (en) 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
OA12323A (en) 2000-03-21 2006-05-15 Smithkline Beecham Corp Protease inhibitors.
AU2001278084A1 (en) 2000-07-31 2002-02-13 The Regents Of The University Of California Model for alzheimer's disease and other neurodegenerative diseases
US7332494B2 (en) 2000-08-14 2008-02-19 Janssen Pharmaceutica, N.V. Method for treating allergies using substituted pyrazoles
US20050101587A9 (en) * 2000-08-14 2005-05-12 Butler Christopher R. Method for treating allergies using substituted pyrazoles
HK1052705B (en) 2000-08-14 2006-09-29 Ortho-Mcneil Pharmaceutical, Inc. Substituted pyrazole
ES2281434T3 (es) * 2000-08-14 2007-10-01 Ortho-Mcneil Pharmaceutical, Inc. Pirazoles sustituidos.
HU230538B1 (hu) 2000-08-14 2016-11-28 Ortho Mcneil Pharmaceutical, Inc. Szubsztituált pirazolok és ezeket tartalmazó gyógyszerkészítmények
US20070105841A1 (en) * 2000-08-14 2007-05-10 Breitenbucher J G Method for treating allergies using substituted pyrazoles
US20070117785A1 (en) * 2000-08-14 2007-05-24 Butler Christopher R Substituted pyrazoles and methods of treatment with substituted pyrazoles
CN1642973A (zh) 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
US6706754B2 (en) 2000-11-06 2004-03-16 The United States Of America As Represented By The Secretary Of The Army Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
WO2002036588A2 (en) * 2000-11-06 2002-05-10 U.S. Army Medical Research And Materiel Command Reversed amidines and methods of using for treating, preventing, or inhibiting leishmaniasis
HUP0303540A2 (hu) * 2000-12-20 2004-01-28 Bristol-Myers Squibb Pharma Co. Diaminok mint kemokin receptor aktivitás modulátorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CA2432369A1 (en) 2000-12-20 2002-08-08 Bristol-Myers Squibb Pharma Company Cyclic derivatives as modulators of chemokine receptor activity
EP1385822A1 (en) 2001-03-09 2004-02-04 Ortho-McNeil Pharmaceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
US6710061B2 (en) 2001-03-09 2004-03-23 Ortho-Mcneil Pharamceutical, Inc. Aminopyrrolidine sulfonamides as serine protease inhibitors
US6982263B2 (en) 2001-06-08 2006-01-03 Boehringer Ingelheim Pharmaceuticals, Inc. Nitriles useful as reversible inhibitors of cysteine proteases
US6780985B2 (en) 2001-11-08 2004-08-24 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of Canine Cathepsin S
US6784288B2 (en) 2001-11-08 2004-08-31 Ortho-Mcneil Pharmaceutical, Inc. Polynucleotide and polypeptide sequences of monkey cathepsin S
US6977256B2 (en) * 2001-11-14 2005-12-20 Aventis Pharmaceuticals Inc. Compounds and compositions as cathepsin S inhibitors
DE10231574A1 (de) 2002-07-11 2004-01-29 Sartorius Ag Membran, Vorrichtung und Verfahren zum Entfernen von Proteasen aus Flüssigkeiten
US7384970B2 (en) * 2003-03-24 2008-06-10 Irm Llc Inhibitors of cathepsin S
US7109243B2 (en) * 2003-03-24 2006-09-19 Irm Llc Inhibitors of cathepsin S
US7173051B2 (en) * 2003-06-13 2007-02-06 Irm, Llc Inhibitors of cathepsin S
US7256207B2 (en) * 2003-08-20 2007-08-14 Irm Llc Inhibitors of cathepsin S
US20060122266A1 (en) * 2004-08-11 2006-06-08 Photini Sinnis Methods and compositions for malaria prophylaxis
CN101674853B (zh) * 2007-05-04 2013-03-27 玛瑞纳生物技术有限公司 氨基酸脂质及其用途
AU2008350907A1 (en) * 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2198879A1 (en) 2008-12-11 2010-06-23 Institut Curie CD74 modulator agent for regulating dendritic cell migration and device for studying the motility capacity of a cell
GB201218084D0 (en) * 2012-10-09 2012-11-21 Univ Aston Novel compounds and methods for use in medicine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3859337A (en) * 1969-06-11 1975-01-07 Stauffer Chemical Co Ethylenediaminetetraacetic acid anhydride derivatives
IT1150959B (it) * 1980-06-10 1986-12-17 Simes Sostanze datate di attivita' antispastica vasale e procedimenti per la loro preparazione
JPH0832698B2 (ja) * 1987-05-08 1996-03-29 日本ケミファ株式会社 ピペラジン誘導体
CA2073776A1 (en) * 1990-11-15 1992-05-16 Joerg Stuerzebecher Meta-substituted phenyl alanine derivatives
AU1354292A (en) * 1991-03-18 1992-10-21 Pentapharm Ag Parasubstituted phenylalanine derivates
CZ245994A3 (en) * 1993-02-10 1995-10-18 Pentapharm Ag Piperazides of substituted phenylalanine derivatives as thrombin inhibitors

Also Published As

Publication number Publication date
NO975742L (no) 1998-02-05
CZ390697A3 (cs) 1998-04-15
ZA964751B (en) 1997-01-08
EP0832099A1 (en) 1998-04-01
JPH11507045A (ja) 1999-06-22
KR19990022395A (ko) 1999-03-25
WO1996040737A1 (en) 1996-12-19
NZ309560A (en) 1999-08-30
AU723658B2 (en) 2000-08-31
CA2222972A1 (en) 1996-12-19
TW438591B (en) 2001-06-07
CN1192219A (zh) 1998-09-02
US6030946A (en) 2000-02-29
AR002328A1 (es) 1998-03-11
PL323710A1 (en) 1998-04-14
AU5975596A (en) 1996-12-30

Similar Documents

Publication Publication Date Title
NO975742D0 (no) Reversible cysteinproteasehemmere
NO974403D0 (no) Reversible proteasehemmere
ATE259352T1 (de) Cysteine protease inhibitoren
NO20006716D0 (no) Proteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
NO20012980D0 (no) Proteaseinhibitorer
ZA951573B (en) Cysteine protease inhibitors
FI961886L (fi) Ihmisen Kunitz-tyyppiset proteaasi-inhibiittorit
FI933277A7 (fi) Amiinidioli proteaasi-inhibiittorit
NO992492D0 (no) Benzamidoaldehyder og deres anvendelse som cystein-protease-inhibitorer
ATE264339T1 (de) Serine protease inhibitoren
FI973282A0 (fi) Trombiinin inhibiittoreita
NO996578D0 (no) Urokinase-inhibitorer
DK0858464T3 (da) Thrombin-inhibitorer
NO995435D0 (no) Protease-inhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO995434D0 (no) Proteaseinhibitorer
BR9610075A (pt) Inibidores prolil endopeptidase
NO20011388D0 (no) Hydroksamat-inneholdende cystein- og serinproteasehemmere
BR9610514A (pt) Inibidores cicloantihelmínticos
BR9612344A (pt) Inibidores de proteases
MA26429A1 (fr) Inhibiteurs de protease
ZA969078B (en) Inhibitors of cysteine protease.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application